[Form 4/A] First Tracks Biotherapeutics, Inc. Amended Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
First Tracks Biotherapeutics director John P. Schmid received new equity awards as part of his compensation. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting in equal monthly installments over 12 months starting June 12, 2026. He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment, which vest in full on the date of the company’s 2027 annual meeting of shareholders, as long as he continues to provide service to the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Schmid John P.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 2,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 7,000 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Unit — 2,500 shares (Direct, null);
Stock Option (right to buy) — 7,000 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
